Skip to main content
. 2020 Jun 24;12(6):1670. doi: 10.3390/cancers12061670

Figure 4.

Figure 4

Differential metabolomics profile of cisplatin resistant HN30 clones. (A) Differential metabolic pathways enrichment differentiates the clones from the HN30 parental line. (B) Two tier topology mapping of the metabolite data identifies a set of metabolites which are different between the clones and the HN30 parental line (C).